Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Scinopharm Taiwan Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, KATAKAM, SUDHAKAR, who is the busiest examiner for the company with 1 pending action. The prosecution is occurring within 1 distinct art unit, which suggests a specialized focus for the current pharmaceutical claims.
The presence of 1 pending office action means that the portfolio's immediate success is tied to the decisions of 1 distinct examiner. KATAKAM, SUDHAKAR is the examiner currently reviewing pending claims, so the prosecution strategy should be tailored to the specific tendencies of this individual. The 1 distinct art unit involved will dictate the procedural standards for the 1 pending action. This centralized arrangement in Biotechnology & Pharmaceuticals means that the outcome of the 1 action will have a significant impact on the portfolio's current status at the patent office. Practitioners can focus their efforts on a single set of examiner expectations rather than managing multiple prosecution tracks.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KATAKAM, SUDHAKAR | 1 | 74.7% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18318869 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | KATAKAM, SUDHAKAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18318869 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | KATAKAM, SUDHAKAR | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18318869 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | KATAKAM, SUDHAKAR | 1658 | §102§103§112 | Final Rejection | — | Pending | May 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial